The tyrphostin NT157 suppresses insulin receptor substrates and augments therapeutic response of prostate cancer

Insulin-like growth factor (IGF) signaling is associated with castrate-resistant prostate Cancer (CRPC) progression. Insulin Receptor substrates 1 and 2 (IRS1/2) mediate mitogenic and antiapoptotic signaling from IGF1 receptor (IGF1R), Insulin Receptor, and Other oncoproteins. This study demonstrates that IRS1/2 expression is increased in prostate Cancer, and persists in CRPC. Furthermore, this study assesses the Anticancer activity of NT157, a small molecule tyrphostin targeting IRS proteins, using androgen-responsive (LNCaP) and -independent (PC3) prostate Cancer cells in vitro and in vivo. NT157 treatment resulted in dose-dependent inhibition of IGF1R activation, suppression of IRS protein expression, inhibition of IGF1-induced Akt activation, but increased ERK activation in NT157-treated cells in vitro. These effects were correlated with decreased proliferation and increasing Apoptosis of LNCaP cells and increasing G2-M arrest in PC3 cells. NT157 also suppressed androgen-responsive growth, delayed CRPC progression of LNCaP xenografts, and suppressed PC3 tumor growth alone and in combination with docetaxel. This study reports the first preclinical proof-of-principle data that this novel small molecule tyrosine kinase inhibitor suppresses IRS1/2 expression, delays CRPC progression, and suppresses growth of CRPC tumors in vitro and in vivo. Demonstration that IRS expression can be increased in response to a variety of stressors that may lead to resistance or reduced effect of the therapies indicate that NT157-mediated IRS1/2 downregulation is a novel therapeutic approach for management of advanced prostate Cancer.